Medicare Advantage has spent the better part of the last decade becoming one of the largest and most important parts of the Medicare program.

More than half of eligible Medicare beneficiaries are now enrolled in Medicare Advantage, and with that growth has come something else: a much larger federal price tag.

A new analysis from KFF estimates that Medicare will spend at least $13.4 billion in 2026 through the Medicare Advantage Quality Bonus Program. That is up from $12.7 billion in 2025 and more than four times the roughly $3 billion spent on quality bonuses in 2015.

On the surface, the idea behind the program is fairly easy to defend.

Medicare Advantage plans are rated on a five-star scale. Plans that achieve at least four stars can qualify for higher Medicare payments. The theory is straightforward: reward plans for quality, give insurers a financial reason to improve, and ultimately create a better experience for Medicare beneficiaries.

But $13.4 billion is enough money that it is worth asking a more difficult question.

What exactly is Medicare getting for it?

The Quality Bonus Program Has Become Big Business

Quality bonuses are no longer a small side program.

According to KFF, about 68% of Medicare Advantage enrollees — nearly 24 million people — are enrolled in plans qualifying for higher payments through the Quality Bonus Program in 2026.

Interestingly, that percentage is actually down.

In 2025, approximately 75% of Medicare Advantage enrollees were in bonus-eligible plans. The 2026 figure is the lowest share since 2018.

Yet federal spending on the bonuses is still expected to rise.

That alone tells us something about how large the Medicare Advantage program has become and how significant these payment adjustments can be.

KFF estimates total Medicare payments to Medicare Advantage plans will be approximately $574 billion in 2026. The $13.4 billion attributed to quality bonuses represents about 2.3% of that total.

And KFF considers its $13.4 billion estimate a lower bound. MedPAC has estimated the effect of the quality bonus adjustment on risk-adjusted benchmarks could add roughly $16 billion to Medicare spending in 2026.

This isn't pocket change anymore.

Who Gets the Money?

The distribution of these bonuses is also interesting.

KFF estimates that UnitedHealth Group will receive the largest increase in Medicare payments associated with the Quality Bonus Program in 2026: approximately $3.9 billion.

Kaiser Foundation Health Plans, meanwhile, has the highest estimated bonus payment per enrollee at $577.

Payment increases also vary by type of Medicare Advantage plan. Employer- and union-sponsored plans have the highest average increase, at $466 per enrollee, while Special Needs Plans have the lowest, at $318.

None of this automatically means the money is being wasted.

A highly rated plan serving millions of Medicare beneficiaries would naturally receive a large amount of bonus funding.

The more important question is whether the rating system accurately measures the kind of quality beneficiaries actually experience.

That is where things become more complicated.

What Does a Four-Star Plan Really Mean?

Most Medicare agents are familiar with star ratings.

Consumers see them on Medicare Plan Finder. Agents see them while comparing plans. Carriers advertise them. A five-star rating can even create a special enrollment opportunity.

The stars carry weight.

But a star rating isn't necessarily a simple measurement of whether an individual Medicare Advantage plan is "good."

Ratings incorporate numerous quality and performance measures, and they generally apply at the contract level. One Medicare Advantage contract can contain multiple plans with different premiums, benefits, provider networks, service areas and even different types of enrollee populations.

That creates an obvious limitation.

A beneficiary isn't enrolling in an abstract contract.

They're enrolling in a specific plan, in a specific county, with a specific provider network and a specific set of benefits.

That distinction matters.

A four- or five-star contract can still contain a plan that is a poor fit for a particular beneficiary.

Likewise, a lower-rated contract might contain a plan that works extremely well for someone's doctors, medications and financial situation.

This is one of the reasons star ratings should be useful information, but not the final answer.

The Consumer Experience Is More Complicated Than a Star

For an insurance broker sitting across from a Medicare beneficiary, "quality" often looks very different from a government score.

Can the client see their cardiologist?

Is their hospital in network?

Are their prescriptions covered?

How difficult is prior authorization?

Can they get an appointment?

What happens when they need rehabilitation or skilled nursing care?

How responsive is the plan when something goes wrong?

And perhaps most importantly: will the plan still be a good fit next year?

Those questions are difficult to compress into a single number.

That doesn't make the star-rating system meaningless. Measuring quality across a program serving tens of millions of people is extraordinarily difficult, and standardized measurements can give consumers information they otherwise wouldn't have.

But we should be careful about confusing a measurement system with quality itself.

There is a difference.

The Incentives Matter

The original logic behind quality bonuses makes sense.

If the government is going to pay private insurers to administer Medicare benefits, rewarding better performance sounds preferable to paying every plan exactly the same regardless of quality.

The problem comes when billions of dollars begin depending on the measurement.

At that point, the measurement itself becomes enormously important.

Insurers have a powerful financial incentive to improve whatever metrics determine the star rating. Ideally, improving those metrics also improves care.

But policymakers have questioned whether the current system always accomplishes that.

KFF notes that MedPAC and others have criticized the star-rating system for having too many measures, inadequately accounting for social risk factors and measuring quality at the contract rather than individual plan level.

CMS is already changing the system. Several administrative measures and measures that CMS says no longer meaningfully differentiate quality are scheduled to be removed for future star ratings.

Ironically, those changes themselves are projected to increase Medicare Advantage spending by $18.6 billion over ten years, in part because more plans are expected to qualify for bonuses.

That illustrates how sensitive the Medicare Advantage payment system has become.

Change the measurement, and billions of dollars can move.

The Bigger Medicare Advantage Debate

It would be easy to take the $13.4 billion number and use it as another argument that Medicare Advantage is simply too expensive.

That would also miss part of the story.

Medicare Advantage is popular for a reason.

Millions of beneficiaries willingly choose these plans every year. Many receive low or zero-dollar premiums, maximum out-of-pocket protection and supplemental benefits such as dental, vision, hearing, fitness programs and other services not generally included in Original Medicare.

For many beneficiaries, Medicare Advantage provides real value.

The question isn't whether Medicare Advantage should exist or whether insurers should ever earn additional payments.

The better question is whether Medicare is paying the right amount for the value being delivered.

That distinction is important.

The federal government has an obligation to protect taxpayers and the long-term financial stability of Medicare. It also has an obligation to maintain a competitive marketplace where insurers have a reason to offer strong benefits, build provider networks, improve service and innovate.

Push payments too high and taxpayers overpay.

Push them too low and plans respond by reducing benefits, narrowing networks, increasing cost sharing or leaving markets altogether.

We have already seen how quickly carrier behavior can change when the economics of Medicare Advantage tighten.

There is no free lunch on either side of this equation.

What This Means for Agents and Brokers

For agents, the KFF analysis reinforces something that is becoming increasingly important.

Medicare Advantage is entering an era of greater scrutiny.

Risk adjustment, coding intensity, star ratings, quality bonuses, prior authorization, supplemental benefits and overall Medicare Advantage payment levels are increasingly being examined by policymakers.

Agents may never need to explain the mechanics of quality bonus benchmarks to the average client.

But agents do need to understand the environment carriers are operating in.

When government reimbursement changes, plan design eventually changes.

When star ratings change, payments can change.

When payments change, benefits, premiums, networks, commissions and carrier participation can eventually change with them.

The consumer often sees the last step.

The broker needs to understand the steps that came before it.

That is one reason the role of an independent Medicare broker is becoming more complicated, not less.

Simply knowing which plan has the largest dental benefit isn't enough.

The better broker understands the carrier, the network, the drug coverage, the client's needs and increasingly the financial pressures shaping the market itself.

A $13 Billion Question

The Medicare Advantage Quality Bonus Program began with a fairly simple proposition: reward higher quality.

In 2026, that proposition comes with a price tag of at least $13.4 billion.

That doesn't prove the program is a failure.

It doesn't prove the money is being wasted.

And it certainly doesn't prove that highly rated Medicare Advantage plans aren't providing value to beneficiaries.

But when a quality incentive grows from roughly $3 billion to more than $13 billion in a little over a decade, it deserves scrutiny.

The question should not simply be whether a plan earned four stars.

The question should be whether those stars represent meaningful improvements that beneficiaries can actually feel when they use their coverage.

Because ultimately Medicare isn't spending billions of dollars to produce better ratings.

It is supposed to be spending that money to produce better healthcare.

Those two things should be the same.

The future of the Quality Bonus Program may depend on how confidently policymakers, taxpayers, agents and — most importantly — Medicare beneficiaries can say that they are.